Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967380 · ClinicalTrials.gov registry record · NA
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02967380 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 14 participants.
The verdict
NCT02967380, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain. Gadobutrol is a type of contrast agent that may increase DCE-MRI sensitivity for the detection of tumors or other diseases of the central nervous system. It is not yet known whether gadobutrol is more effective than standard of care contrast agents before DCE-MRI in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain.
Interventions
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Gadobutrol
- DRUG Gadobenate Dimeglumine
- RADIATION Gadopentetate Dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-12-14 |
| Est. Completion | 2015-10-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967380
The ClinicalTrials.gov registry entry for NCT02967380 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dynamic Contrast-Enhanced Magnetic Resonance Imaging is the first listed.
NCT02967380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02967380 about?
NCT02967380 is a clinical study titled "Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases". This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have sp...
What is the current status of trial NCT02967380?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2011-12-14. Estimated completion is 2015-10-14.
What interventions are being tested in trial NCT02967380?
The interventions under investigation include: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Gadobutrol (DRUG), Gadobenate Dimeglumine (DRUG), Gadopentetate Dimeglumine (RADIATION).
Who is sponsoring clinical trial NCT02967380?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.